Abstract
Background/Aim: Osteosarcoma is a recalcitrant neoplasm which occurs predominantly in adolescents and young adults. Recently, using a patient-derived orthotopic xenograft (PDOX) model of malignant soft-tissue sarcoma (STS), we showed that oral recombinant methioninase (o-rMETase), in combination with caffeine, was more efficacious than o-rMETase alone in inhibiting STS tumor growth. In the present report, we determined the efficacy of o-rMETase combined with oral caffeine on a cisplatinum (CDDP)-resistant osteosarcoma PDOX model. Materials and Methods: Osteosarcoma PDOX models were randomly divided into seven treatment groups (6 mice in each group): untreated control; CDDP alone; o-rMETase alone; o-rMETase with caffeine; CDDP plus o-rMETase; CDDP plus caffeine; and CDDP plus o-rMETase with caffeine. Tumor size and body weight were measured throughout the treatment. Results: Tumors regressed after treatment with CDDP plus o-rMETase with caffeine. Tumors treated with CDDP plus o-rMETase with caffeine also had the most necrosis. Conclusion: The combination of o-rMETase and caffeine together with first-line chemotherapy was efficacious for drug-resistant osteosarcoma and has clinical potential in the treatment of this highly-resistant neoplasm.
Osteosarcoma is the most frequent primary malignant bone tumor. Osteosarcoma is generally treated with a combination of various chemotherapy drugs and surgery (1). Cisplatinum (CDDP) has been the most effective therapeutic option for osteosarcoma, but outcome remains poor for most osteosarcoma patients when they develop chemoresistance (2).
Restriction of methionine (MET) selectively arrests cancer cells in S/G2 with subsequent apoptosis (3). Cancer cells are highly dependent addicted on MET and their need of MET is restricted by a recombinant methioninase (rMETase). We have previously demonstrated that cancer cells arrested by MET restriction orally a are highly sensitive to caffeine because it induces mitotic catastrophe (4). We recently reported that oral rMETase (o-rMETase) inhibited tumor growth in a chemoresistant malignant soft-tissue sarcoma (STS) patient derived orthotopic xenograft (PDOX) model, and that combining o-rMETase with oral caffeine increased its efficacy (4). In addition, the tumor was regressed by adding this combination to first-line drug doxorubicin (DOX) (4). Thus, we consider that the administration of o-rMETase and caffeine together with chemotherapy is a promising strategy which could overcome chemoresistance.
In this study, we analysed the efficacy of combining o-rMETase and caffeine in overcoming CDDP-resistance in an osteosarcoma PDOX model.
Efficacy of chemotherapy on the osteosarcoma-PDOX model. (a) Treatment regime. (b) Line graphs show tumor volume at each time point during treatment relative to the initial tumor volume for each treatment and control group. N=6 mice per treatment group. *p<0.05; **p<0.01; ***p<0.001. Error bars: ±SEM.
Materials and Methods
Animals. Athymic nu/nu nude mice (AntiCancer, Inc., San Diego, CA, USA), 4-6 weeks old, were used (5). All experimental methods and data collection were carried based on our previous publications (4, 5). Anesthesia and analgesics were used to reduce any suffering of the animals as previously reported (5, 6). All mouse studies were performed at AntiCancer, Inc. An Institutional Animal Care and Use Committee (IACUC) protocol particularly approved for the present study were followed per the principles and procedures described in the National Institutes of Health (NIH) Guide for the Care and Use of Animals under Assurance Number A3873-1 (5, 6).
Patient-derived tumor. In this study, a fresh biopsy sample of a 14-year-old boy with osteosarcoma in pelvis was used (6). The sample was processed at AntiCancer, Inc. The procedures of cutting small fragments and their subcutaneous implantation in nude mice have been previously described (5). No chemotherapy or radiotherapy was provided to the patient prior to biopsy (5). Written informed consent was obtained from the patient as part of the University of California, Los Angeles (UCLA) Institutional Review Board approved protocol (IRB#10-001857) (6).
Establishment of an osteosarcoma PDOX model. The procedure for establishing osteosarcoma PDOX model including subcutaneously-implantation, harvesting of tumors, cutting them into small fragments, mice anesthesia and wound closure with nylon suture has been previously described (5-7).
Recombinant methionase (rMETase) production. rMETase production has been described previously (8).
Treatment regimen for the osteosarcoma PDOX model. The osteosarcoma PDOX mouse models were randomly divided into 7 groups (6 mice each) (Figure 1a). Mice were treated for 2 weeks using the following drugs: G1, untreated control; G2, CDDP (6 mg/kg, intraperitoneal (i.p.) injection, once a weekl) alone (6); G3, o-rMETase (100 units/day for 14 consecutive days, oral administration) alone; G4, o-rMETase + caffeine (100 mg/kg/day for 14 consecutive days, oral administration); G5, CDDP + o-rMETase; G6, CDDP + caffeine; G7, CDDP + o-rMETase + caffeine. Treatment started once tumors were reached 100 mm3 (6). Tumor volume and body weight measurements were performed twice a week (6-8). The formula to calculate tumor volume has been previously described (6-8). Data are presented as mean±standard error of the mean (SEM).
Histological analysis. Samples were fixed, sectioned and stained as previously reported (6-8).
Statistical analysis. All statistical analyses were performed as previously reported (6-8). All p-values were two-sided and p-values of less than 0.05 were regarded as statistically significant.
Results
Efficacy of the tested drugs on the osteosarcoma-PDOX. No significant inhibition of osteosarcoma PDOX was obtained when tumors were treated with CDDP alone, o-rMETase alone, or with o-rMETase + caffeine compared with control: Control vs. CDDP: p=0.91; vs. o-rMETase: p=0.48; vs. o-rMETase + caffeine; p=0.18. In contrast, mice treated with CDDP + o-rMETase, CDDP + caffeine, and CDDP + o-rMETase + caffeine showed significant inhibition of tumor growth compared to control: Control vs. CDDP + o-rMETase: p=0.02; vs. CDDP + caffeine: p=0.003; vs. CDDP + o-rMETase + caffeine: p<0.001. Tumor regression was observed only in the mice treated with CDDP + o-rMETase + caffeine. Significant differences were found in tumor growth between the CDDP + o-rMETase + caffeine treated group, and all the other treatment groups except for the CDDP + caffeine treated group: CDDP + o-rMETase + caffeine vs. CDDP: p<0.001; vs. o-rMETase: p<0001; vs. o-rMETase + caffeine: p<0.001; vs. CDDP + rMETase: p=0.008) (Figures 1b and 2).
Images of representative osteosarcoma-PDOX model from each treatment group at the end of treatment. (a) Untreated control. (b) CDDP alone. (c) o-rMETase alone. (d) o-rMETase + caffeine. (e) CDDP + o-rMETase. (f) CDDP + caffeine. (g) CDDP + o-rMETase + caffeine. Arrows show the margins of the tumors. Scale bars: 10 mm. (h) relative tumor volume for each drug treatment on day 14.
Histology of the osteosarcoma-PDOX. The untreated tumor (control) was specifically composed of viable highly-dense tumor cells which had spindle-shaped cells with extensive pleomorphism, many mitotic figures, and bizarre appearing cells with hyperchromatic nuclei (6). In addition, osteoid laid down in a lace-like pattern in between the tumor cells was also seen (6). Tumors treated with CDDP, o-rMETase alone, o-rMETase and caffeine, CDDP plus o-rMETase, CDDP plus caffeine comprised viable tumor cells, although the tumor cell density was lower compared to the control group, and degenerative scar change in the stroma cells was also observed. Extensive tumor necrosis with increased inflammatory cell infiltration was seen in tumors treated with CDDP plus o-rMETase and caffeine. The strong anti-tumor efficacy of CDDP plus o-rMETase and caffeine treatment on osteosarcoma-PDOX tumor was demonstrated (Figure 3a-g).
Effect of treatment on body weight. Mean body weight of the mice significantly increased in control (p<0.001) and o-rMETase treated group (p<0.001). However, no significant difference was found in body weight between pre- and post-treatment in any other treatment group (Figure 3h). No other side effects or animal deaths were observed in any treatment group.
Discussion
Osteosarcoma is a frequently occurring malignant bone tumor in young people. Osteosarcoma patients have a very poor 5-year survival rate, because osteosarcoma is a highly aggressive neoplasm that shows poor response to chemotherapy drugs (9). It is often treated with a combination of chemotherapy drugs, and surgery (1). CDDP has been used as an effective drug for osteosarcoma, however, outcome remains poor for most osteosarcoma patients once they develop chemoresistance (2, 10, 11).
The present results suggest that the osteosarcoma-PDOX is methionine-dependent since it responds to o-rMETase. Combining caffeine with o-rMETase can increase its efficacy against the osteosarcoma-PDOX tumor, which was further strongly enhanced by adding CDDP.
Tumor histology and mouse body weight. (a) untreated control. (b) CDDP. (c) o-rMETase. (d) o-rMETase + caffeine. (e) CDDP + o-rMETase. (f) CDDP + caffeine. (g) CDDP + o-rMETase + caffeine. Arrows indicate tumor osteoid. Scale bars: 100 μm. (h) Mouse body weight (g) is depicted in bar graphs for each treatment group or control group at pre- and post-treatment times. ***p<0.001; Error bars: ±SEM.
CDDP, DOX, and high-dose methotrexate are generally given to osteosarcoma patients either alone or in combination, as a first-line treatment (1, 6). Survival of osteosarcoma patients has improved greatly in the past few decades due to these chemotherapy drugs. However, the survival rate decreases to 30-40% if the tumor is CDDP resistance (2, 12).
Cancer cells are MET-dependent (Hoffman effect) because they excessively utilize MET for aberrant transmethylation reactions (12), which is similar to a situation when cancer cells utilize excess amount of glucose (Warburg effect) (13, 14). PET imaging of cancer with [11C]MET provides a robust signal compared to fluorodeoxyglucose [18F]FDG suggesting that the Hoffman effect is considerably prominent compared to the Warburg effect (15).
We recently reported that combining caffeine to o-rMETase increased the efficacy of rMETase by lowering plasma L-MET levels compared to o-rMETase alone (4), and addition of o-rMETase and caffeine in combination with DOX resulted in regression of a DOX-resistant synovial sarcoma (SS) PDOX (4). In the present study, o-rMETase and caffeine combination with CDDP was effective and induced regression of the osteosarcoma-PDOX tumor, perhaps due to induction of mitotic catastrophe by caffeine on rMETase S/G2-arrested cancer cells (4). Combining o-rMETase and caffeine with CDDP could overcome CDDP-resistance in osteosarcoma without observable toxicity.
In conclusion, the present study determined that o-rMETase could inhibit tumor growth of osteosarcoma-PDOX and combining o-rMETase with caffeine could increase its efficacy. Adding CDDP to this combination regressed the osteosarcoma-PDOX tumor and overcame CDDP-resistance in osteosarcoma, suggesting an important clinical potential of this strategy.
Footnotes
Authors' Contributions
Conception and design: TH and RMH. Acquisition of data: TH, HO, KM, NS, QH, YN, JP, ZZ, SR. Analysis and interpretation of data: TH, HO, KM, NS, QH, YN, JP, ZZ, SR, NY, KH, HK, SM, KI, MB, SPC, SRS, HT, and RMH. Study supervision: RMH. Manuscript writing/revision of the manuscript: TH, RMH and SRS. All Authors reviewed the manuscript.
Conflicts of Interest
AntiCancer Inc. uses PDOX models for contract research. TH, HO, KM, NS, QH, YN, JP, ZZ, SR, and RMH are or were unsalaried associates of AntiCancer Inc. The authors have no other competing financial interests.
- Received July 1, 2019.
- Revision received July 9, 2019.
- Accepted July 10, 2019.
- Copyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved
References
In this issue
Jump to section
Related Articles
Cited By...
- Selective Synergy of the Combination of Recombinant Methioninase With Cisplatinum and Ivermectin Which Eradicates Lung-Cancer Cells but Has No Synergy and Limited Effect on Normal Fibroblasts
- Triple Combination of Recombinant Methioninase and the Anti-parasitic Drugs Ivermectin, and Chloroquine Selectively Eradicates Pancreatic Cancer Cells While Sparing Normal Fibroblasts
- Engineered Methioninase-expressing Tumor-targeting Salmonella typhimurium A1-R Inhibits Syngeneic-Cancer Mouse Models by Depleting Tumor Methionine
- Super Methotrexate-resistant Osteosarcoma Cells Retain Their Sensitivity to Recombinant Methioninase: Targeting Methionine Addiction to Overcome Extreme Cancer-Chemotherapy Resistance
- Comparison of Cell-death Kinetics of Recombinant Methioninase (rMETase)-treated Cancer and Normal Cells: Only Cancer Cells Undergo Methionine-depletion Catastrophe at Low rMETase Concentrations
- Selective Synergy of Recombinant Methioninase Plus Docetaxel Against Docetaxel-resistant and -sensitive Fibrosarcoma Cells Compared to Normal Fibroblasts
- Recombinant Methioninase Synergistically Reverses High-docetaxel Resistance Developed in Osteosarcoma Cells
- Recombinant Methioninase Increases Eribulin Efficacy 16-fold in Highly Eribulin-resistant HT1080 Fibrosarcoma Cells, Demonstrating Potential to Overcome the Clinical Challenge of Drug-resistant Soft-tissue Sarcoma
- Overcoming High Trabectedin Resistance of Soft-tissue Sarcoma With Recombinant Methioninase: A Potential Solution of a Recalcitrant Clinical Problem
- Recombinant Methioninase Is Selectively Synergistic With Doxorubicin Against Wild-type Fibrosarcoma Cells Compared to Normal Cells and Overcomes Highly-Doxorubicin-resistant Fibrosarcoma
- DNA-Binding Agent Trabectedin Combined With Recombinant Methioninase Is Synergistic to Decrease Fibrosarcoma Cell Viability and Induce Nuclear Fragmentation But Not Synergistic on Normal Fibroblasts
- Extensive Synergy Between Recombinant Methioninase and Eribulin Against Fibrosarcoma Cells But Not Normal Fibroblasts
- [11C] Methionine-PET Imaging as a Cancer Biomarker for Methionine Addiction and Sensitivity to Methionine-restriction-based Combination Chemotherapy
- Elimination of Axillary-Lymph-Node Metastases in a Patient With Invasive Lobular Breast Cancer Treated by First-line Neo-adjuvant Chemotherapy Combined With Methionine Restriction
- Oral Installation of Recombinant Methioninase-producing Escherichia coli into the Microbiome Inhibits Colon-cancer Growth in a Syngeneic Mouse Model
- Stage IV Pancreatic Cancer Patient Treated With FOLFIRINOX Combined With Oral Methioninase: A Highly-Rare Case With Long-term Stable Disease
- Methionine Restriction: Ready for Prime Time in the Cancer Clinic?
- Oral-recombinant Methioninase Converts an Osteosarcoma from Methotrexate-resistant to -sensitive in a Patient-derived Orthotopic-xenograft (PDOX) Mouse Model
- Osteosarcoma Patient-derived Orthotopic Xenograft (PDOX) Models Used to Identify Novel and Effective Therapeutics: A Review
- Over-methylation of Histone H3 Lysines Is a Common Molecular Change Among the Three Major Types of Soft-tissue Sarcoma in Patient-derived Xenograft (PDX) Mouse Models
- The Combination of Cisplatinum and Doxorubicin Regressed Primary Osteosarcoma of the Breast in a PDOX Mouse Model
- Multikinase-Inhibitor Screening in Drug-resistant Osteosarcoma Patient-derived Orthotopic Xenograft Mouse Models Identifies the Clinical Potential of Regorafenib
- The First Mouse Model of Primary Osteosarcoma of the Breast
- Combination of CDK4/6 and mTOR Inhibitors Suppressed Doxorubicin-resistant Osteosarcoma in a Patient-derived Orthotopic Xenograft Mouse Model: A Translatable Strategy for Recalcitrant Disease
- Chronic Treatment of an Advanced Prostate-cancer Patient With Oral Methioninase Resulted in Long-term Stabilization of Rapidly Rising PSA Levels
- Eribulin Inhibits Osteosarcoma in a Clinically-accurate Bone-tumor-insertion PDOX Mouse Model
- Oral-recombinant Methioninase Converts an Osteosarcoma from Docetaxel-resistant to -Sensitive in a Clinically-relevant Patient-derived Orthotopic-xenograft (PDOX) Mouse Model
- Lowering and Stabilizing PSA Levels in Advanced-prostate Cancer Patients With Oral Methioninase
- A Novel Procedure for Orthotopic Tibia Implantation for Establishment of a More Clinical Osteosarcoma PDOX Mouse Model
- Response of Triple-negative Breast Cancer Liver Metastasis to Oral Recombinant Methioninase in a Patient-derived Orthotopic Xenograft (PDOX) Model
- Oral Recombinant Methioninase Sensitizes a Bladder Cancer Orthotopic Xenograft Mouse Model to Low-dose Cisplatinum and Prevents Metastasis
- Oral Methioninase Inhibits Recurrence in a PDOX Mouse Model of Aggressive Triple-negative Breast Cancer
- Recombinant Methioninase Combined With Tumor-targeting Salmonella typhimurium A1-R Induced Regression in a PDOX Mouse Model of Doxorubicin-resistant Dedifferentiated Liposarcoma
- Oral dosing of Recombinant Methioninase Is Associated With a 70% Drop in PSA in a Patient With Bone-metastatic Prostate Cancer and 50% Reduction in Circulating Methionine in a High-stage Ovarian Cancer Patient
- Oral Recombinant Methioninase Prevents Obesity in Mice on a High-fat Diet
- PPAR{gamma} Agonist Pioglitazone in Combination With Cisplatinum Arrests a Chemotherapy-resistant Osteosarcoma PDOX Model